These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 2890681)
21. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. Rowlett JK; Cook JM; Duke AN; Platt DM CNS Spectr; 2005 Jan; 10(1):40-8. PubMed ID: 15618946 [TBL] [Abstract][Full Text] [Related]
22. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Lippa A; Czobor P; Stark J; Beer B; Kostakis E; Gravielle M; Bandyopadhyay S; Russek SJ; Gibbs TT; Farb DH; Skolnick P Proc Natl Acad Sci U S A; 2005 May; 102(20):7380-5. PubMed ID: 15870187 [TBL] [Abstract][Full Text] [Related]
23. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Nutt DJ; Malizia AL Br J Psychiatry; 2001 Nov; 179():390-6. PubMed ID: 11689393 [TBL] [Abstract][Full Text] [Related]
26. Use of drugs in the treatment of anxiety. Vajda FJ; Burrows GD Aust Fam Physician; 1983 Oct; 12(10):714-7. PubMed ID: 6141784 [TBL] [Abstract][Full Text] [Related]
27. [Neurobiological approach to anxiety]. Boyer P Arch Mal Coeur Vaiss; 1987 May; 80 Spec No():43-6. PubMed ID: 2889436 [No Abstract] [Full Text] [Related]
28. Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action. Shephard RA Life Sci; 1987 Jun; 40(25):2429-36. PubMed ID: 2884549 [TBL] [Abstract][Full Text] [Related]
29. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. Klein E J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116 [TBL] [Abstract][Full Text] [Related]
30. The anxiolytic activity of beta-carboline derivatives in mice, and its separation from ataxic properties. Stephens DN; Kehr W; Wachtel H; Schmiechen R Pharmacopsychiatry; 1985 Jan; 18(1):167-70. PubMed ID: 2859620 [No Abstract] [Full Text] [Related]
31. Is tofisopam an atypical anxiolytic? Pellow S; File SE Neurosci Biobehav Rev; 1986; 10(2):221-7. PubMed ID: 2874535 [TBL] [Abstract][Full Text] [Related]
32. New molecular targets for antianxiety interventions. Gorman JM J Clin Psychiatry; 2003; 64 Suppl 3():28-35. PubMed ID: 12662131 [TBL] [Abstract][Full Text] [Related]
34. [The neurobiology of anxiety: current assessment and perspectives]. Tobeña Pallarés A Med Clin (Barc); 1988 May; 90(20):824-30. PubMed ID: 2901514 [No Abstract] [Full Text] [Related]
35. Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety. Chen X; van Gerven J; Cohen A; Jacobs G Acta Pharmacol Sin; 2019 May; 40(5):571-582. PubMed ID: 30518829 [TBL] [Abstract][Full Text] [Related]
36. Benzodiazepines in the treatment of anxiety. Rickels K Am J Psychother; 1982 Jul; 36(3):358-70. PubMed ID: 6128929 [TBL] [Abstract][Full Text] [Related]
37. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. Bailey JE; Papadopoulos A; Seddon K; Nutt DJ J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427 [TBL] [Abstract][Full Text] [Related]
38. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Brogden RN; Heel RC; Speight TM; Avery GS Drugs; 1980 Sep; 20(3):161-78. PubMed ID: 6107238 [TBL] [Abstract][Full Text] [Related]